UKALL14 Phase 1 Standard Induction Therapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Induction of remission in newly diagnosed, previously untreated adult acute lymphoblastic leukaemia (ALL) patients (aged 25-65 years) treated on UKALL14-protocol. | 3 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | BCR::ABL1 | Acute Lymphoid Leukemia | Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Vincristine | |
| HSE (1) | BCR::ABL1, CD20 + | Acute Lymphoid Leukemia | Daunorubicin, Dexamethasone, Imatinib, Methotrexate, Rituximab, Vincristine | |
| HSE (1) | CD20 + | Acute Lymphoid Leukemia | Daunorubicin, Dexamethasone, Methotrexate, Rituximab, Vincristine |